This article is more than 5 years old. Information may no longer be current.
Bionic Vision completes clinical trial of retinitis pigmentosa implant
Bionic Vision Australia announced the completion of the first clinical trial of its prototype 24-channel percutaneous implant for patients with severe vision loss from retinitis pigmentosa.
The 2-year study started in May 2012 and involved three patients with retinitis pigmentosa who had profound vision loss, according to a company press release. Each patient received surgically implanted suprachoroidal electrode implants.
Throughout the study, the implants were stable, with no significant movement and no unexpected adverse events observed.
According to the company, three other programs are ongoing. The first is a 44-channel device that will enter the clinic in mid-2015. The consortium is also developing a 98-channel device and a high acuity device, according to the press release.